ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0040

Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function

Andrew Gibson1, Jianming Wu2, Chaoling Dong1, R. Curtis Hendrickson1, Travis Ptacek1, Jeffrey Edberg1 and Robert Kimberly1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Minnesota, Saint Paul, MN

Meeting: ACR Convergence 2025

Keywords: Fc receptors, signal transduction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0019–0048) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The Tyrosine Activation Motif (ITAM)-containing FcRg chain, encoded by FCER1G, non-covalently couples with the immunoglobulin binding receptors, — FcγRI (CD64), FcγRIIIa (CD16), and FcaRI (CD89), — to initiate intracellular signals and mediate phagocytosis, cytokine production and other functions. While functionally impactful variants have been identified in the ligand-binding alpha-chains of receptors associated with FcRg, variants in the signal-generating FcRg have not been explored. Signal modulation through structural variants at the level of FcRγ would have implications for all FcRγ-associated receptors and their role in the pathogenesis of immune-mediated diseases.

Methods: We carried out in silico analyses of whole genome DNA sequence databases based on short read sequencing (eg, gnomAD with ~79,000 genomes) and long-read sequencing (eg, >600 genomes from All of Us, the Arab and Chinese Pangenomes, and local long-read sequenced cohorts). We also assessed whole exome sequences (eg, gnomAD, UK Biobank and Regeneron totally >1M participants) as well as RNA transcript databases. We used Sanger sequencing of cDNAs derived from FcRg mRNAs isolated from local participants to confirm ESTs (eg, BG548748) in circulating immune cells. We used hg38 reference genome to identify genomic DNA and cDNA structural variants at the single nucleotide and larger variant levels.

Results: In the human genome, insertions, deletions and rearrangements of FCER1G are absent, and with the exception of very rare single nucleotide variants (allele frequency < 0.01), the FcRγ protein is monomorphic. Surprisingly, we confirmed that in addition to the canonical FcRγ transcript encoding the classically recognized FcRγ protein, an alternatively spliced (AS) form of FcRg message encodes a translated protein (AS-FcRg) which is expressed in human myeloid cells. AS-FcRγ is able to pair with ligand binding α-chains. The incorporation of the alternate exon 5’ in AS-FcRγ creates a novel cytoplasmic domain with a disrupted ITAM signaling motif (Figure 1). The AS-FcRg mRNA is expressed in cell lines (U937, THP-1, HL-60) and in circulating neutrophils, monocytes and platelets, but not in lymphocytes, from normal donors. Co-immunoprecipitation experiments show that AS-FcRg associates with FcaRI in circulating neutrophils and mononuclear cells (Figure 2). An engineered chimeric molecule consisting of the extracellular domain of FcaRI fused to the cytoplasmic domain of AS-FcRg fails to stimulate cellular degranulation and cytokine production (Figure 3)

Conclusion: The AS-FcRg variant is not signaling competent and may represent a novel inhibitory mechanism limiting the ability of Fc receptors to stimulate cellular signaling in myeloid cells with important implications for host defense and antibody-mediated autoimmune diseases, including SLE and RA.

Supporting image 1Figure 1. Sequence of FcRγ isoforms. The partial amino acid sequences of WT-FcRγ and AS-FcRγ are shown. Exon 5’ in AS-FcRγ replaces exon 5 and encodes a novel cytoplasmic domain with no traditional signaling motifs. The ITAM signaling motif [ YxxL(x7)YxxL ] present in the WT-FcRγ is highlighted.

Supporting image 2Figure 2. Western blot analysis of FcαR1 immunoprecipitates showing that AS-FcRγ protein pairs with and co-precipitates with FcαR1 in monocytes (MNC) and neutrophils (PMN).

Supporting image 3Figure 3. Stimulation of AS-FcRγ chimeric construct. A) Degranulation of β-Hexosaminidase activity. RBL-2H3 cells stably expressing vector alone or a chimeric receptor consisting of the extracellular domain of FcαRI fused to the cytoplasmic domain of WT-FcRγ or AS-FcRγ were stimulated with anti-FcαRI antibody A59 F(ab’)2 for the times indicated. Cell degranulation was measured as a percent of total β-Hexosaminidase released by triton X-100 treated cells. B) IL-4 cytokine production. RBL-2H3 cells stably expressing the chimeric receptors were stimulated as outlined above for the indicated times. Cell culture media was then assayed by ELISA for the presence of IL-4 cytokine.


Disclosures: A. Gibson: None; J. Wu: None; C. Dong: None; R. Hendrickson: None; T. Ptacek: None; J. Edberg: None; R. Kimberly: None.

To cite this abstract in AMA style:

Gibson A, Wu J, Dong C, Hendrickson R, Ptacek T, Edberg J, Kimberly R. Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/identification-of-a-novel-expressed-alternatively-spliced-fcer1g-protein-that-inhibits-receptor-function/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-a-novel-expressed-alternatively-spliced-fcer1g-protein-that-inhibits-receptor-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology